Drugs / Antitumor B
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT04278989 | Apr 2022 → May 2025 | oral cavity squamous cell carcinoma | Medical College of Wisconsin | Completed | No outcome recorded |
| Phase 0 | NCT03459729 | Aug 2021 → Feb 2022 | oral cavity squamous cell carcinoma | Medical College of Wisconsin | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Antitumor B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03459729 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “Anti-tumor B is a botanical agent composed of six Chinese herbs: Sophora tonkinensis, Polygonum bistorta, Prunella vulgaris, Sonchus brachyotus, Dictamnus dasycarpus, and...” NCT04278989 ↗ |